These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16193002)

  • 21. Clinical trials end at gene-therapy institute..
    Smaglik P
    Nature; 2000 Jun; 405(6786):497. PubMed ID: 10850679
    [No Abstract]   [Full Text] [Related]  

  • 22. All clear for HIV-targeting ribozyme in phase II.
    Brower V; Chahine K; Dorey E; Dove A; Francisco M; Hodgson J; Michael A; Marshall A
    Nat Biotechnol; 1998 Feb; 16(2):123. PubMed ID: 9487501
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical aspects of ribozymes as therapeutics in gene therapy.
    Looney D; Yu M
    Methods Mol Biol; 1997; 74():469-86. PubMed ID: 9204462
    [No Abstract]   [Full Text] [Related]  

  • 24. Rapid 1-hour transduction of whole bone marrow leads to long-term repopulation of murine recipients with lentivirus-modified hematopoietic stem cells.
    Kurre P; Anandakumar P; Kiem HP
    Gene Ther; 2006 Feb; 13(4):369-73. PubMed ID: 16208421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
    Anderson J; Akkina R
    Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
    Neschadim A; McCart JA; Keating A; Medin JA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene therapy: mastering the basics, defining details.
    Jenks S
    J Natl Cancer Inst; 1997 Aug; 89(16):1182-4. PubMed ID: 9274908
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
    ter Brake O; Legrand N; von Eije KJ; Centlivre M; Spits H; Weijer K; Blom B; Berkhout B
    Gene Ther; 2009 Jan; 16(1):148-53. PubMed ID: 18668146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. More flexibility on reporting to federal agencies about injuries to research subjects.
    Maloney DM
    Hum Res Rep; 2002 Jan; 17(1):1-2. PubMed ID: 16270435
    [No Abstract]   [Full Text] [Related]  

  • 30. Toll-like receptor 7 and MyD88 knockdown by lentivirus-mediated RNA interference to porcine dendritic cell subsets.
    Alves MP; Neuhaus V; Guzylack-Piriou L; Ruggli N; McCullough KC; Summerfield A
    Gene Ther; 2007 May; 14(10):836-44. PubMed ID: 17330086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA comments on phase I clinical trials without vector biodistribution data.
    Epstein S; Bauer S; Miller A; Pilaro A; Noguchi P
    Nat Genet; 1999 Aug; 22(4):326. PubMed ID: 10431234
    [No Abstract]   [Full Text] [Related]  

  • 32. Building an HIV-proof immune system.
    Cohen J
    Science; 2007 Aug; 317(5838):612-4. PubMed ID: 17673648
    [No Abstract]   [Full Text] [Related]  

  • 33. Cancer risk prompts US to curb gene therapy.
    Check E
    Nature; 2003 Mar; 422(6927):7. PubMed ID: 12621402
    [No Abstract]   [Full Text] [Related]  

  • 34. Gene therapy progress and prospects: cystic fibrosis.
    Griesenbach U; Geddes DM; Alton EW
    Gene Ther; 2006 Jul; 13(14):1061-7. PubMed ID: 16819538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lentiviral vectors for gene therapy of heart disease.
    Higuchi K; Medin JA
    J Cardiol; 2007 Jan; 49(1):1-11. PubMed ID: 17269208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
    Li M; Li H; Rossi JJ
    Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy.
    Capowski EE; Schneider BL; Ebert AD; Seehus CR; Szulc J; Zufferey R; Aebischer P; Svendsen CN
    J Neurosci Methods; 2007 Jul; 163(2):338-49. PubMed ID: 17397931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermia studies begin.
    AIDS Patient Care STDS; 1996 Oct; 10(5):314. PubMed ID: 11361536
    [No Abstract]   [Full Text] [Related]  

  • 39. The future of gene therapy.
    Cavazzana-Calvo M; Thrasher A; Mavilio F
    Nature; 2004 Feb; 427(6977):779-81. PubMed ID: 14985734
    [No Abstract]   [Full Text] [Related]  

  • 40. [Construction of a novel gene therapy lentiviral vector for drug resistant selection and detection in vivo].
    Xu C; Gu Y; Hou W; Cheng T; Zhang T; Que Y; Gao S; Zhang J; Han J; Xia N
    Sheng Wu Gong Cheng Xue Bao; 2008 Feb; 24(2):256-61. PubMed ID: 18464610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.